Diabetes drug shows promise against fatty liver
NCT ID NCT06117137
First seen Apr 23, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This study looked at whether a class of diabetes drugs called SGLT2 inhibitors can improve fatty liver disease in people with type 2 diabetes. 150 adults with both conditions took part. Researchers measured changes in liver stiffness, fat levels, and blood sugar control after 6 months of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FATTY LIVER, NONALCOHOLIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Faculty of medicine Sohag university hospital
Sohag, Egypt
Conditions
Explore the condition pages connected to this study.